KdT VenturesExpanding the Drug Delivery ToolboxToday our ability to treat many diseases is limited only by our ability to effectively deliver genetic medicines.9 min read·Sep 15, 2022----
KdT VenturesState of the Market: The GoalpostsBefore I start, let me get two things out of the way. First, in no way am I the caller of market tops and bottoms — and that’s not the…4 min read·May 9, 2022----
KdT VenturesThe Bioproduction BattleThe globalization that began during the 1990s and flourished into this millennia reshaped aspects of our lives in ways we are only now…7 min read·May 2, 2022----
KdT VenturesHow health insurance DAOs can break up RWD silosKdT has recently been exploring alternative data sharing incentive structures, since as a firm we believe the greatest advancements in…11 min read·Feb 14, 2022----
KdT VenturesZymergen: A Cautionary TaleAs we continue to digest the news from Zymergen and its reverberations across the Synthetic Biology ecosystem, we wanted to take a moment…2 min read·Aug 5, 2021----
KdT VenturesThe World in a Grain of SandContent is king (or so my kids tell me). We would like to be able to say that we have a grand plan in mind behind launching curated content…2 min read·May 13, 2021----
KdT VenturesWhat $50M in New Capital Means for EntrepreneursToday we’re announcing the closing of our $50M Fund II for KdT Ventures. With the announcement, one important aspect is obvious: with this…2 min read·Mar 23, 2021----
KdT VenturesPartnering and FocusN.B.- As a reminder, we are a seed-stage firm so our views relate to companies at that seed stage.3 min read·Jan 26, 2021----
KdT VenturesThe Golden Age of Microfluidics?Lately, it feels like a disproportionately large number of companies we have seen at KdT deploy or manipulate microfluidic technology of…2 min read·Jan 6, 2021----
KdT VenturesHow Platforms Can Think Intelligently About Early Deal StructureBefore jumping in headfirst, it’s important to acknowledge relevant qualifiers:5 min read·Jun 29, 2020----